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Summary
Evaluation of — Ryo A, Tsurutani N, Ohba K et al.: SOCS1 is an inducible host factor during HIV-1
infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc. Natl Acad. Sci.
USA 105, 294-299 (2008).
Gag is an essential HIV protein that is responsible for assembling infectious viral particles. The jour-
ney of Gag from synthesis to virion formation is an attractive target for anti-HIV therapy. While a
lot is known about the cellular factors required for virion assembly and budding, relatively little is
known about factors required for Gag trafficking. Ryo and colleagues provide the first evidence of
such a factor, the suppressor of cytokine signaling 1 (SOCS1). They demonstrated that SOCS1 is im-
portant for Gag stability and plays a critical role in its trafficking within the cell. Without SOCS1 Gag
accumulates in perinuclear bodies and is degraded by lysosomes. This article therefore highlights
a new and novel target for stopping the production of HIV, a target that belongs to the relatively
invariant host rather than the rapidly evolving virus.
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Introduction
The suppressor of cytokine signaling 1 (SOCS1) protein was recently reported as an essential cofactor
for HIV-1 Gag stability and trafficking [23]. Gag has become a hot topic in HIV research in recent
years and is seen as a novel target for developing antiretrovirals. Indeed the Gag-targeting drug
bevirimat/PA-457 is now past Phase I/II clinical trials and entering Phase IIb trials [25]. Bevirimat
binds to Gag in the immature virion and blocks the final protease-mediated cleavage event required
to mature the virion, thereby rendering HIV noninfectious. Much, however, is still unknown about
where Gag traffics and with what cellular factors it interacts with on its itinerary from synthesis to
virion incorporation. The work by Ryo and colleagues adds an important piece to this puzzle and
their paper is the first to provide a detailed molecular picture of a cellular factor involved in Gag
trafficking.
Gag is an essential polyprotein whose role is to form and direct the assembly of virus particles [22].
Gag is cleaved into its constituent proteins [matrix (MA), capsid (CA), spacer peptide 1 (SP1), nucleo-
capsid (NC), spacer peptide 2 (SP2) and p6] by the HIV protease following virion budding andmatu-
ration, but remains a polyprotein during virion assembly within the cell. Several reports demonstrate
that Gag needs to interact with numerous cellular proteins on its way to or at the budding membrane
[15]. Most of these proteins are associated with the endosomal sorting system of the cell and leads to
the controversial hypothesis that late endosomes or multivesicular bodies are sites of virion assembly
in addition to the plasma membrane [18, 19, 6, 27].
SOCS1, by contrast, is not associated with the endosomal sorting system. SOCS1 and other members
of the SOCS family play an important role in modulating cytokine-induced intracellular signaling
pathways [5]. SOCS1 expression is upregulated when various cytokines bind their cognate receptors
and initiate the JAK/STAT signaling cascade. In a negative feedback loop, SOCS1 suppresses the
signaling cascade by various mechanisms including inhibiting the kinase activity of JAKs and redi-
recting JAK2 for proteasomal degradation. In vivo studies in mice suggest that SOCS1 acts as a brake
to counter the potentially toxic consequences of cytokine activation [8].
Summary of Methods and Results
The finding by Ryo and colleagues that HIV-1 can induce SOCS1 expression is very novel [23]. The
authors noticed SOCS1 in gene array studies of cellular genes upregulated by HIV-1 infection. They
confirmed the upregulation of SOCS1 transcription in both a T-cell line and healthy donor peripheral
blood mononuclear cells (PBMCs) infected in vitro with HIV-1. Cotransfection of an adherent cell
line with HIV-1 proviral DNA (pNL4–3) and a SOCS1 expression plasmid showed a dose-dependent
increase in virion production and intracellular Gag levels. These increases depended on the SH2
and SOCS box domains of SOCS1. Electron microscopy and replication kinetics data suggested that
SOCS1 was promoting the production of infectious virions rather than noninfectious virus-like par-
ticles.
The team confirmed that SOCS1 interacts with Gag in a series of in vitro experiments. They found
that only the SH2 domain of SOCS1 (most likely amino acids 100 – 107) was required for binding
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to recombinant Gag. Both the MA and NC domains of Gag can independently bind SOCS1 in vitro,
but heterologous domain substitution experiments implied that functional interaction is with MA.
Confocal microscopy experiments of cells overexpressing SOCS1 and a Gag-green fluorescent pro-
tein fusion (Gag-GFP) implied the two proteins may also interact within the cell. However, more
convincing tests of intracellular interaction could have been used, such as fluorescence resonance
energy transfer (FRET) [2].
One of the functional consequences of Gag–SOCS1 interaction is an increase in Gag stability. Pulse-
chase experiments with pNL4–3 showed that SOCS1 extended the protein half-life of intracellular
Gag and caused CA to appear earlier in the culture supernatant. In an attempt to visualize this by
microscopy, confocal experiments were performed in cells cotransfected with pNL4–3 and SOCS1
plasmid. The authors used an anti-CA antibody to detect Gag but did not visualize SOCS1. They
claimed SOCS1 increased Gag levels in the cytoplasm and at the plasma membrane, but the data pre-
sented in the paper are not strong. Confocal experiments of cycloheximide-treated cells transfected
with Gag-GFP instead of pNL4–3 did reveal an increase of Gag-GFP at the plasma membrane when
SOCS1 was overexpressed. The authors quantitated the amount of Gag-GFP at the plasma mem-
brane but how they did this is unclear and whether they accounted for changes in Gag-GFP stability
is unknown.
The final series of experiments explored the effects of knocking down endogenous SOCS1 using
RNAi. Suppressing SOCS1 expression resulted in reduced intracellular Gag levels and decreased
virion production, corroborating the earlier overexpression experiments. Knockdown also signifi-
cantly reduced HIV-1 replication in both the Jurkat T cell line and CD4+ T cells isolated from healthy
donor PBMCs. Confocal experiments revealed prominent perinuclear accumulations of Gag-GFP
when SOCS1 expression was suppressed. These accumulations overlapped with lysozyme, a marker
for lysosomes. Treatment of SOCS1-depleted cells with ammonium chloride, which prevents lyso-
some acidification, increased Gag-GFP signals by western blot. So it appears that SOCS1 increases
Gag stability by preventing its destruction in lysosomes, thereby promoting virion production and
viral infectivity.
Discussion
Overall the data presented by Ryo and colleagues clearly demonstrate that:
• HIV-1 can induce SOCS1 expression
• SOCS1 promotes infectious virion production
• SOCS1 achieves this by increasing Gag stability in the cell
What is unclear is the extent of SOCS1’s involvement in Gag trafficking. As a result the paper raises
many important questions. Does SOCS1 foster proper trafficking of Gag or does it indirectly enable it
by increasing Gag’s half-life? The perinuclear accumulation of Gag-GFP in the absence of SOCS1 ex-
pression coincides with observations made by Perlman and Resh, who described newly synthesized
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Gag-GFP transiently accumulating around the cell nucleus before trafficking to the plasma mem-
brane [19]. Are these perinuclear aggregates a normal destination for Gag, for example to pick up
viral and cellular RNA for virion incorporation [20, 17]? Is SOCS1’s role then to redirect Gag from
these aggregates to sites of virion assembly before Gag gets degraded by lysosomes?
Ryo and colleagues demonstrated that the SOCS box domain of SOCS1 is crucial for its effect on
virion production. SOCS1 indirectly interacts with E3 ubiquitin ligases via its SOCS box, thereby
promoting the ubiquitination of JAK2 during the regulation of cytokine signaling [5]. Could SOCS1
also direct the ubiquitination of Gag? Evidence suggests that Gag ubiquitination is important for
virion assembly and viral infectivity [11, 10]. Ubiquitination is thought to allow Gag to interact with
and co-opt members of the endosomal sorting system required for transport (the ESCRT complexes
[14]) for the purposes of virion production [9, 7, 21]. The trans-Golgi network-associated protein
SH3RF1 (hPOSH) is the only E3 ubiquitin ligase known to directly interact with Gag, but it’s unlikely
to ubiquitinate Gag itself [1]. Thus it will be important to determine if SOCS1 can promote Gag
ubiquitination, thereby cementing a key role of SOCS1 in Gag trafficking as well as Gag stability.
Future Perspective
Ryo and colleagues end their paper by suggesting SOCS1 as a therapeutic target. Indeed this was
proposed in 2006 (albeit from a different perspective) when Song and coworkers used RNAi against
SOCS1 to enhance anti-HIV responses in mice [26]. In that study murine dendritic cells (DCs) were
transduced with lentivirus expressing a siRNA against SOCS1. These SOCS1-suppressed DCs were
loaded with HIV envelope (Env) protein before being injected into mice. Song and colleagues re-
ported enhanced T- and B-cell-mediated immune responses against Env followingDC immunization.
This enhancement lasted at least 6 months post-immunization and also worked when the SOCS1
siRNA was formulated as part of a DNA vaccine strategy. Thus silencing SOCS1 in certain immune
cells appears to enhance broad anti-HIV immunity in vivo.
One of the concerns of this vaccine approach, even one designed to perturb Gag trafficking, is the
long-term effects of SOCS1 suppression on the immune system [12]. Song and colleagues did not
observe any obvious signs of pathology 7 months after the mice were immunized with the SOCS1-
suppressed DCs [26], but the same may not be the case in humans. SOCS1 is required for curtailing
interferon-mediated inflammation [4], reducing DC-mediated autoimmunity [13] and also appears
to play an anti-cancer role [5]. So any vaccine utilising SOCS1 suppression will need to monitor
for signs and symptoms of these pathologies. It has also been shown in vitro that types I and III
interferon can increase HIV-1 uptake and replication in PBMCs owing to upregulated expression of
CD4, CCR5 and CXCR4 receptors [24]. SOCS1 regulates the signaling of both these types of interferon
[3, 8], so it remains to be seen if SOCS1 silencing will increase HIV-1 uptake in vivo. Finally, using
cytokines as adjuvants in anti-HIV therapy has been suggested [16]. Combining cytokine adjuvants
with SOCS1 suppression may further enhance anti-HIV responses, but it may also exacerbate the
problems associated with dysregulated cytokine signaling.
Notwithstanding the above, viewing Gag trafficking and cytokine signaling pathways as drug targets
is different from current antiviral strategies and offers exciting prospects for future HIV therapies.
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The experimental drug bevirimat demonstrates that Gag is a viable option for antiretroviral therapy
[25], andmodulating the host immune response rather than targetingHIV directly, if done safely, may
circumvent some of the issues of viral resistance. Of course better understanding Gag trafficking will
enlighten even more viral and cellular targets for intervention. The paper by Ryo and colleagues is
therefore an important first step in this enlightenment.
Executive Summary
Introduction
• HIV-1 Gag is an essential polyprotein required for virion assembly.
• Research into Gag trafficking is very active as it is seen as a novel area for developing anti-HIV
therapies.
• The paper reviewed herein describes the suppressor of cytokine signaling 1 (SOCS1) as an es-
sential cofactor for Gag stability and trafficking.
• SOCS1 is a cellular protein normally involved in regulating cytokine-induced signaling path-
ways. It does so to prevent toxic side effects of excessive cytokine signaling during immune
activation.
Summary of Methods and Results
• HIV-1 infection induced SOCS1 expression in peripheral blood mononuclear cells.
• Overexpressing SOCS1 in cells increased the production of infectious virus particles and in-
creased intracellular Gag levels.
• Functional interaction was mapped between the SH2 domain of SOCS1 and the matrix domain
of Gag.
• SOCS1 increased the half-life of Gag within the cell, apparently by preventing Gag degradation
by lysosomes.
• SOCS1 overexpression lead to more Gag at the plasma membrane, whereas RNAi-mediated
suppression of SOCS1 caused Gag to accumulate in perinuclear aggregates.
Discussion
• SOCS1 is important for Gag stability, but it’s unclear how SOCS1 directs proper Gag trafficking.
• Further experiments are needed to elucidate the nature of the perinuclear aggregates. (E.g., are
they a normal destination for Gag? Does SOCS1 then redirect Gag to sites of virion assembly?)
• It will be important to determine if SOCS1 can direct the ubiquitination of Gag, as it does for
other proteins. Gag ubiquitination plays an essential role in virion assembly.
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Future Perspectives
• SOCS1 has been proposed as a target for anti-HIV therapy.
• Others have shown that SOCS1-suppressed dendritic cells may be used as an immunothera-
peutic, leading to broad anti-HIV immunity in mice.
• Concerns exist as to the safety of SOCS1 suppression. SOCS1 regulates inflammation, sup-
presses autoimmunity and prevents certain types of cancer.
• Nevertheless, SOCS1 and Gag trafficking are exciting targets for future HIV therapies. Better
understanding of Gag trafficking and interacting factors is therefore needed.
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